Phaseline

Companies › Geron

Geron: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Imetelstat sodium
Telomerase reverse transcriptase inhibitor
TERTPhase 3Myelofibrosis; Myelodysplastic SyndromesFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02598661Imetelstat sodiumPhase 2Myelodysplastic SyndromesHematologyOct 2023
NCT05371964Imetelstat sodiumPhase 1MyelofibrosisOncologyFeb 2027
NCT04576156Imetelstat sodiumPhase 3MyelofibrosisOncologyJun 2028

From the company's SEC filings

Cash of $69m on 2026-09-30; operating cash outflow about $92m a year; runway about 9 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

TERT (1)

Companies with the same targets

–

Companies built like this

Servier Affaires Médicales Karyopharm Therapeutics Can-Fite BioPharma LeonaBio RenovoRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.